C4 Therapeutics shares updated Phase 1 data for multiple myeloma candidate
C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.
The findings, presented as further analysis at the European Hematology Association (EHA) 2026 Congress, demonstrated strong anti-tumor activity and deep clinical responses in patients who had previously undergone heavy prior lines of treatment.
At the recommended Phase 2 dose of 100 micrograms, cemsidomide achieved an overall response rate of 53% when administered in combination with dexamethasone.
The responses included complete remissions characterized by minimal residual disease (MRD) negative status, alongside a median duration of response lasting 7.9 months.
The safety evaluation across the heavily pretreated patient cohort revealed a generally manageable tolerability profile.
While neutropenia occurred frequently among participants, standard clinical protocol adjustments, including temporary dose interruptions and growth factor support, effectively controlled the adverse events, resulting in minimal trial discontinuations due to drug toxicity.
The oncology-focused biotechnology firm is currently advancing the asset through its Phase 2 MOMENTUM trial and exploring further combo regimens to establish cemsidomide as a foundational late-line therapy for multiple myeloma.
